Company news

Share this article:
Lundbeck will acquire Ovation Pharmaceuticals for $900 million, giving the Danish company a US commercial platform, specialty sales force and late-stage pipeline prospects as it prepares for the 2012 expiration of patents on Lexapro, its main product, which it comarkets with Forest Labs. Like Lundbeck, closely held Ovation, based in the Chicago suburb of Deerfield, IL, is focused on CNS drugs, with an emphasis on niche markets with high unmet medical needs. 
 
Demonstrating just how badly advertising agencies are suffering from the recession, Omnicom Group reported that fourth-quarter net income was down 13.7% to $271 million from $313.9 million for the period a year ago. Full-year net income was up 2.5% to $1 billion, and worldwide revenue for the full year was up 5.2% to 13.3 billion, year-on-year. The holding company did not break out how its healthcare units, including names like Cline, Davis & Mann, Corbet Accel and TBWA WorldHealth, are faring.  
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.